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The lack of exposure to helminth infections, as a result of improved living standards and medical conditions, may have contributed
to the increased incidence of IBD in the developed world. Epidemiological, experimental, and clinical data sustain the idea that
helminths could provide protection against IBD. Studies investigating the underlying mechanisms by which helminths might
induce such protection have revealed the importance of regulatory pathways, for example, regulatory T-cells. Further investigation
on how helminths influence both innate and adaptive immune reactions will shed more light on the complex pathways used
by helminths to regulate the hosts immune system. Although therapy with living helminths appears to be effective in several
immunological diseases, the disadvantages of a treatment based on living parasites are explicit. Therefore, the identification and
characterization of helminth-derived immunomodulatory molecules that contribute to the protective effect could lead to new
therapeutic approaches in IBD and other immune diseases.
Copyright © 2008 Nathalie E. Ruyssers et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INFLAMMATORY BOWEL DISEASES AND
THE HYGIENE HYPOTHESIS
Inflammatory bowel diseases (IBDs), such as Crohn’s disease
and ulcerative colitis, are chronic immune diseases of the gas-
trointestinal tract. Although the aetiologies of these diseases
still remain unknown, the current hypothesis indicates that
IBD results from an uncontrolled immune response to the
normal gut flora [1, 2]. Genetic factors and environmental
factors both contribute to the damaging mucosal immune
response [3, 4].
The incidence of IBD has steadily increased in the
developed world since 1950 [5, 6]. According to the hygiene
hypothesis, this is directly related to the higher hygienic
standards in these countries [7, 8]. It is suggested that the
lack of exposure to infectious agents like helminths, as a
result of improved living standards and medical conditions,
modulates the development of the immune system and
thereby increases the risk of immune diseases [9, 10].
The hygiene hypothesis was initially proposed by Stra-
chan in 1989 for hay fever [11] and additional epidemi-
ological studies were performed to further investigate the
link between this hygiene concept and the incidence of
other immunological diseases. As a consequence, the hygiene
hypothesis is now proposed for several immunological disor-
ders such as asthma and allergic diseases [12], cardiovascular
diseases [13], Type 1 diabetes mellitus [14], multiple sclerosis
[15], and IBD [16].
The hygiene hypothesis for IBD is clearly supported
by the geographical distribution of the disease. There is a
well described north-south gradient for the incidence of
IBD. Northern Europe and North America have the highest
IBD incidence rates whereas Crohn’s disease and ulcerative
colitis remain scarce in South America, Africa, and Asia
[6, 17]. However, the gap between high- and low-incidence
areas in northern versus southern regions is narrowing.
In Asia, for example, incidence rates still remain low as
compared to Europe, but they are rapidly increasing [18].
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Changing lifestyle is thought to be the major cause of
the disease increase in low-incidence areas [18]. The most
important factor to explain these geographical differences is
the socioeconomic level [16]. IBD is more frequently seen
among patients with a higher socioeconomic status [19, 20].
Higher socioeconomic levels can be associated with better
sanitation conditions, high-quality water, and better medical
standards [2].
Another factor supporting the hygiene hypothesis is the
inverse relationship between infant mortality rates and the
incidence of IBD. Infant mortality might be linked to worse
hygiene and medical conditions. Countries with high infant
mortality rates consequently have lower reported incidence
of IBD [21].
As mentioned previously, better hygienic circumstances
translate into diminished exposure to infectious agents like
helminths. The absence of such parasitic infections during
childhood renders the immune system more prone to allergic
and immune diseases. Thus infections seem to activate an
important protective factor against these disorders [7]. Iden-
tifying the nature of this protective effect and implementing
this notion in therapeutic strategies against IBD and other
immune diseases is now the challenge for basic research.
2. IMMUNOLOGY OF THE GASTROINTESTINAL TRACT
2.1. Initiating innate and adaptive immune responses
to enteric antigens in the gut
The gastrointestinal tract is continuously exposed to a wide
range of dietary and environmental antigens, both harmless
and pathogenic. Mounting protective immune responses
against harmful pathogens whilst also preventing excessive
responses to harmless antigens from food and bacterial flora
is one of the major dichotomous functions of the mucosal
immune system [22].
There are different levels of host defence that pathogens
have to trespass to induce inflammation. Numerous mecha-
nisms are acting to form a physical barrier to prevent micro-
organisms from gaining access to the underlying tissues.
Production of saliva and mucus, gastric and pancreatic
juices, intestinal peristalsis, and epithelial cells all contribute
to the elimination of pathogens from the gut lumen [23, 24].
Tight junctions between epithelial cells form a barrier to
prevent bacterial pathogens from invading the gut tissue [25–
27]. Once a pathogen breaks through this physical barrier,
innate and adaptive immune responses work closely together
to eliminate the intruder [28].
Antigens in the gut lumen can be taken up via different
transport routes [29]. The innate immune system will
respond to pathogen associated molecular patterns (PAMPs).
As a part of the innate immune system, phagocytes like
monocytes, macrophages and dendritic cells, and cytotoxic
cells like natural killer cells rapidly control the invasion [30].
The adaptive immune system responds to antigens which
have been presented by cells of the innate immune system
[30]. Once antigens are taken up by antigen presenting
cells, such as dendritic cells, fragments of the antigen
are presented to T-cells locally or in mesenteric lymph
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Figure 1: T-cell subsets. Naı¨ve CD4+ T cells are stimulated by
antigen presenting cells and the cytokine environment to proliferate
into a certain subset. There are three distinct effector T-cell subsets
(red): Th1, Th2, and Th17. CD4+ regulatory T-cells (green) can be
subdivided in CD4+CD25+ Treg, Tr1, and Th3 cells. Crohn’s disease
is characterized by Th1, Th17 inflammation, whereas helminths
induce Th2 and regulatory T-cells (modified from [36, 37]).
nodes (MLNs) after migration of the antigen presenting
cells [31, 32]. Adaptive immune responses are initiated by
stimulation of lymphocytes. T-cells will help B lymphocytes
to secrete immunoglobulins, the antigen-specific antibodies
that are responsible for eliminating extracellular pathogens.
On the other hand, T lymphocytes eradicate intracellular
pathogens and mediate, for example, antihelminth and
allergic responses [23]. Adaptive immune responses improve
on repeated exposure to a given antigen by the formation of
B and T memory cells [28].
2.2. T cell subsets and the immunological basis of
helminth therapy in IBD
T lymphocytes are characterized by their cell-surface anti-
gens called CD (cluster of differentiation) antigens. A
common CD antigen found on all T-cells is the CD3
molecule which forms an essential part of the T-cell receptor
and is important in the recognition of antigens presented
by antigen presenting cells [33]. Within this pool of T
lymphocytes, a difference is made between cytotoxic T-
cells (CD8+) and helper T-cells (CD4+). CD4+ T-cells
can orchestrate the functional activity of both innate and
adaptive immune systems by “helping” macrophages, NK
cells, CD8+ T-cells, and B cells. These T helper (Th) cells can
be divided into several subsets of CD4+ cells and each subset
is suited for coordinating the effector activities that best
combat the invading pathogen [34]. CD4+ T lymphocytes
can be classified into distinct populations based on the
cytokines they produce (Figure 1) [35–37].
Effector CD4+ T cells are divided into three distinct
lineages. T helper 1 (Th1) cells are engaged in the eradication
of intracellular pathogens (e.g., intracellular bacteria and
viruses) and are characterized by the production of IL-
2, IL-12, and IFN-γ [38]. Gastrointestinal inflammation
during Crohn’s disease is Th1 mediated [23]. T helper 2
(Th2) cells stimulate B-cell antibody production, eosinophil
recruitment and mucosal expulsion mechanisms and are
characterized by the secretion of IL-4, IL-5, and IL-13
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[38]. Th2 cells enhance elimination of parasitic helminth
infections and support allergic responses. During helminth
infection, the host evokes a strong Th2 immune response
to provide protection against worm colonization [39]. The
cytokines produced by Th1 and Th2 cells crossregulate
each other’s development and activity, for example, IFN-
γ produced by Th1 cells amplifies Th1 development and
inhibits proliferation of Th2 cells [35]. In this way, helminths
can evoke an immune response that might be able to
attenuate the Th1 response found during Crohn’s disease.
A third lineage of effector CD4+ cells has been recently
discovered and is characterized by the production of IL-
17, the Th17 cell. IL-17 induces expression of many innate
inflammatory mediators such as IL-6, acute phase proteins,
granulocyte-colony stimulating factor, and prostaglandin E2.
Th1 and Th2 cytokines can inhibit Th17 development, while
Th1 and Th2 effector cells seem resistant to IL17 expression
[40]. It is now clear that the Th17 pathway is critical for the
development of inflammation. IL17 is elevated in a variety of
inflammatory conditions as shown for rheumatoid arthritis,
asthma, and recently IBD [41]. Furthermore, it has been
shown that IL-23 supports the proliferation of Th17 cells.
IL-23 is mainly produced by activated myeloid cells such
as macrophages and dendritic cells. The discovery of this
new IL-23/IL-17 pathway was a major breakthrough in the
immunopathogenesis of IBD and the exact role of this axis
needs to be further defined [41, 42]. Investigation of the
effect of helminth infections on the IL-23/IL-17 pathway
may uncover additional immunological pathways by which
helminths can provide protection against immune disorders.
Aside from these effector T-cells, another population
of CD3+ cells called regulatory T (Treg) cells have been
described. Treg cells have immunosuppressive function and
cytokine profiles distinct from either Th1, Th2, or Th17
T-cells [43]. By suppressing excessive Th1, Th2, or Th17
immune responses, Treg cells play an important role in
the maintenance of self-tolerance, thus preventing autoim-
mune diseases, as well as inhibiting harmful inflammatory
diseases such as asthma and inflammatory bowel disease
[44]. There is emerging evidence that distinct subgroups of
CD4+, CD8+, and natural killer T cells mediate immune
regulatory mechanisms [45]. The most attention is being
paid to the CD4+ Treg cells which can be subdivided into
different subsets. These include the natural CD4+CD25+
Treg cells, which inhibit immune responses through cell-cell
contact and through the production of immunosuppressive
cytokines, type 1 Tr (Tr1) cells which secrete high levels
of IL-10 and type 3 T (Th3) cells which primarily secrete
TGF-β [43]. Treg lymphocytes suppress the differentiation
of both Th1 and Th2 lymphocytes and are considered real
gatekeepers of the mucosal immune response [2].
The balance between Th1, Th2, and Treg cells is of
special interest in the gastrointestinal immune system. The
gut provides a unique microenvironment prone to Treg
cell differentiation. This microenvironment is characterized
by the constant exposure to commensal flora and food
antigens and by the presence of immunomodulatory factors
and cytokines that participate in the differentiation of the
mucosal immune system [22]. Defects of the regulatory
mechanisms may lead to development of specific Th1- or
Th2- mediated diseases.
Given that helminths induce a distinct immunological
mechanism compared to IBD, worms can be used as
immunomodulators to downregulate the immune response
in IBD. Helminths induce Th2 and Treg cells which are
capable of suppressing Th1 effector cells, the cells responsible
for maintenance of inflammation in IBD patients.
3. HELMINTHS AS THERAPEUTIC AGENTS IN IBD
3.1. Experimental and clinical studies supporting
helminth-based therapy
Helminths colonize more than one third of the world
population [46]. In developed countries, these parasites have
been largely eradicated as a public health concern due to
the availability of efficacious drugs and better sanitation
conditions [47]. In developing countries, however, helminth
colonization is still common [48]. As shown by epidemiolog-
ical studies, there is an inverse relation between the frequency
of worm colonization and the prevalence of IBD [46]. It was
Elliott et al. who first proposed the hypothesis that the loss
of exposure to parasitic worms increased the risk of IBD
[49, 50].
Preliminary data of Elliott et al. illustrating a protective
response of Schistosoma mansoni infection on trinitroben-
zene sulphate (TNBS)-induced colitis in mice [49] have led
to several experimental animal studies investigating the effect
of helminth infections on IBD [2]. The first full study on
helminth modulation of experimentally induced colitis was
published by Reardon et al. in 2001. They showed that
infection of mice with the tapeworm Hymenolepis diminuta
ameliorated dextran sodium sulphate (DSS)-induced colitis
[51]. Khan et al. subsequently showed that infection with
the nematode, Trichinella spiralis, protected mice from
colitis induced by intrarectal challenge with dinitrobenzene
sulphate (DNBS) [52]. Elliott et al. demonstrated that
schistosome eggs had a protective effect on TNBS-induced
colitis in mice [53] and that Heligmosomoides polygyrus
could reduce established colitis in IL-10 deficient mice
[54]. We previously demonstrated a protective effect of
infection with the blood fluke, Schistosoma mansoni, on
trinitrobenzene sulfonic acid (TNBS)-induced colitis in rats
[55]. Taken together, different helminth parasites (nematode,
cestode, and trematode) can ameliorate colitis in different
experimental animal models [56]. Furthermore, helminths
also protect against other immunological diseases as shown
in rodent models for asthma [57], type 1 diabetes mellitus
[14], and experimental autoimmune encephalomyelitis [17,
58].
Based on the promising findings of helminth infections
on experimental colitis, clinical studies were initiated. Treat-
ment of patients with the porcine whipworm, Trichuris suis,
resulted in clinical amelioration of both Crohn’s disease and
ulcerative colitis [59, 60]. In the same line, a proof of concept
study showed clinical efficacy of experimental infection
with the human hookworm Necator americanus on Crohn’s
disease [61]. Clinical trials of Necator americanus in asthma
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Figure 2: Effect of Schistosoma mansoni soluble worm proteins
(SmSWPs) and Ancylostoma caninum excretory/secretory products
(AcESPs) on myeloperoxidase (MPO) activity. MPO activity was
measured to monitor the degree of myeloid cell infiltration in
the colon. Data are presented as units MPO per gram of colon
tissue and 1 unit equals the amount of MPO necessary to degrade
1 μmol of H2O2 to H2O per minute at 25◦C. TNBS-induced colitis
caused a significant increase in MPO activity compared to control
mice treated with phosphate-buffered saline (PBS). Intraperitoneal
injection of helminth-derived products significantly ameliorated
inflammation as shown by the significant decrease in MPO activity.
Treatment of control mice with SmSWP or AcESP had no effect
(data not shown). ∗ p ≤ .05, significantly different from contol
PBS; # p ≤ .05, significantly different from TNBS-PBS; two way
ANOVA, n = 7− 10 [77].
are being organized [62]. An international multicentre
clinical trial is in preparation (awaiting FDA approval) to
further investigate the clinical efficacy of helminth-based
therapy in IBD [2].
3.2. The use of helminth-derived molecules
as therapeutic agents
Although helminth infections appear to be effective against
IBD, treatment of patients with living helminths may
envision drawbacks. Persistent infection and/or invasion of
the parasite (particularly zoonotic ones) to other tissues in
the human host, where they might cause pathology, should
be considered [63, 64]. In 2006, Kradin et al. reported
that treatment of a pediatric Crohn’s disease patient with
five oral doses of Trichuris suis ova caused infection with
living sexually immature worms in the ileocecal region and a
sexually mature male worm within the cecum [64]. Although
helminths may be beneficial in the treatment of IBD,
using living helminth ova can lead to infection, therefore,
therapeutic human helminth colonization needs to be closely
examined for potential adverse side effects. Furthermore,
intestinal helminths influence gastrointestinal physiology.
Infection with certain nematodes may induce enhanced
intestinal propulsive activity, goblet cell hyperplasia, and
increased mucus secretion [65]. As a consequence, intestinal
helminths may alter gastrointestinal motility, possibly result-
ing in intestinal symptoms like diarrhoea and abdominal
cramps [65]. Moreover, the idea of being infected with a
living parasite could be psychologically hard to accept for
some patients. Therefore, treatment with immunologically
active helminth molecules might overcome the possible
disadvantages of a therapy with living parasites.
Identification and characterization of helminth-derived
immunomodulatory molecules that contribute to the anti-
colitis effect could lead to new therapeutic approaches in
IBD without the need for helminth infection [56, 66].
Using parasite extracts or synthetic drugs designed to mimic
the disease-modulating effect of helminth molecules also
allows greater flexibility in dosing routes and therapeutic
applications [67].
Helminths possess evolved mechanisms to turn off
proinflammatory cascades by secreting and expressing cer-
tain molecules [37]. Multiple studies have characterized a
broad spectrum of helminth-derived immunomodulatory
products. A detailed review of these products is beyond the
scope of this paper so we will bring only some molecules
of interest into focus. Maizels et al. showed that the
filarial nematode Brugia malayi produces homologues of
the mammalian cytokine TGF-β. Bm-tgh-2 is secreted by
adult worms and binds to mammalian TGF-β receptors
thus performing an immunomodulatory function in the
host [39]. Helminths secrete cysteine protease inhibitors
which interfere with antigen presentation and increase IL-
10 secretion from macrophages [68]. Helminth-derived
carbohydrates contribute to the induction of Th2 immune
responses [69]. Lacto-N-fucopentaose III is the predominant
carbohydrate component of Schistosmamansoni egg antigens
and this glycan stimulates the secretion of Th2 cytokines
[70]. Harnett et al. recently showed that the phosphoryl-
choline part of the glycoconjugate ES-62, secreted by filarial
nematodes, is responsible for its anti-inflammatory action
in arthritis [71]. Research focusing on the development
of vaccines against helminth infections also showed the
effectiveness of helminth antigens as immunomodulators.
Vaccination studies against Schistosomiasis are focusing on
the protective effect of several Schistosoma antigens [72]. Vac-
cination studies against human hookworm infections tested
recombinant excretory/secretory (ES) products from L3
larval stages of Ancylostoma caninum and promising results
were observed [73–75]. Furthermore, vaccination studies
against hookworm infection revealed that administration
of a cocktail of recombinant antigens has an improved
protective effect compared to the protection achieved with
separate antigens [76].
In respect to IBD, there is need for in-depth experi-
mental studies on the effect of helminth antigens on colitis.
We are currently investigating the therapeutic potential of
protein mixtures of Schistosoma mansoni and Ancylostoma
caninum on TNBS-induced colitis in mice. As shown in
Figure 2, preliminary experiments showed that both S.
mansoni soluble worm proteins and A. caninum ES products
attenuated TNBS-induced inflammation of the murine colon
[77]. These results indicate that the beneficial effect of
treatment with living worms on experimental colitis may be
reproduced with soluble extracts of helminths. Yang et al.
showed that Schistosoma japonicum egg antigens inhibited
the development of asthma in a murine model [57]. S.
mansoni antigens are also able to modulate innate immune
responses and prevent onset of type 1 diabetes [78]. These
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studies indicate that treatment with helminth extracts may
be as effective as treatment with living helminths and that
the achieved protection is not specific for just one helminth
species. Isolated helminth proteins may provide a more
readily acceptable form of therapy for patients than living
worms.
4. CONCLUDING REMARKS
The hygiene hypothesis suggests an inverse relationship
between parasitic infections and the incidence of IBD.
Epidemiological, experimental, and clinical data sustain the
idea that helminths could provide protection against IBD.
The importance of regulatory pathways such as regulatory
T-cells, by which helminths induce such protection have
been described. However, the complex pathways helminths
activate to regulate the host’s immune system need further
investigation. Helminths influence innate as well as adaptive
immune responses and this knowledge can contribute to
new therapeutic approaches of helminth-induced protection.
Therapy with living helminths appears to be effective in
several immunological diseases. A logical next step, to avoid
the possible disadvantages of a treatment with living para-
sites, is the identification and characterization of helminth-
derived immunosuppressive molecules that contribute to the
protective effect.
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